Klin Farmakol Farm. 2007;21(2):54-58

Adverse effects of antiepileptic therapy in children and adolescents with epilepsy - retrospective analysis

Ĺubomír Virág2, Magdaléna Kuželová1, Lívia Magulová3,2, Miroslav Murgaš4
1 Katedra farmakológie a toxikológie, Farmaceutická fakulta UK, Bratislava
2 Oddelenie klinickej farmakológie, Fakultná nemocnica Nitra, Nitra
3 II. interná klinika, Fakultná nemocnica, Nitra
4 Neštátna detská neurologická ambulancia, Nitra

Anticonvulsants are drugs for a longtime therapy, therefore their possible adverse effects require more attention. The aim of study was to obtain data about adverse effects and overall risk of antiepileptic therapy in paediatric patients with epilepsy.

Methods: We analyse the adverse effects of antiepileptic drugs used by paediatric patients, who were treated in private paediatric neurological practice in Nitra during 10 years time (1994–2004). Over this period, there were 219 patients treated with the diagnosis of epilepsy in this ambulance. Medical records of these patients have provided the source of data.

Results: One hundred sixteen (53 %) patients were treated by monotherapy. Valproate was the most often used antiepileptic drug. Adverse effects of anticonvulsants were presented at almost 30 % of patients. Most of the adverse reactions had less serious character and developed after the treatment with both valproate and carbamazepine. The most frequent adverse effects were gastrointestinal problems (39 %), central nervous system problems (37 %), skin eruptions (14 %) and malfunction of haemopoiesis (9 %). Serious (idiosyncratic) adverse effects (acute pancreatitis after valproate therapy, toxoallergic exanthema after carbamazepine, exocentric constriction of visual field after vigabatrine) were reported to the National monitoring centre for the adverse reactions of drugs in Bratislava.

Conclusion: Our results point out on the fact that the therapy by classic antiepileptics (phenytoin, valproate and carbamazepine) is connected by relatively frequent incidence of the adverse reactions. Therefore, it is necessary to monitor actively anamnestic, clinical and laboratory warning manifestation of possible adverse reaction.

Keywords: epilepsy, children, anticonvulsants, adverse effects

Published: October 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Virág Ĺ, Kuželová M, Magulová L, Murgaš M. Adverse effects of antiepileptic therapy in children and adolescents with epilepsy - retrospective analysis. Klin Farmakol Farm. 2007;21(2):54-58.
Download citation

References

  1. Greenwood SR. Adverse effects of antiepileptic drugs. Epilepsia 2000;41:42-52. Go to original source... Go to PubMed...
  2. Temple ME, Robinson RF, Miller JC et al. Frequency and preventability of adverse drug reactions in paediatric patients. Drug Saf 2004;27(11):819-829. Go to original source... Go to PubMed...
  3. Sýkora P. Epidemiológia epilepsie. Lekár. listy 2004;7:26.
  4. Devinsky O, Cramer J. Safety and efficacy of standard and new antiepileptic drugs. Neurol 2000;55:5-10.
  5. Leppik I E. Monotherapy and polypharmacy. Neurol 2000;55:25-29.
  6. Donáth V. Iatrogénna problematika antiepileptík. Neurol pre prax 2003;3:116-121.
  7. Ježová D, Kuchar M, Kriška M. Antiepileptiká. In: Kriška M, eds. Riziko liekov v medicínskej praxi. SAP, spol. s.r.o., Bratislava, 2000:366-379.
  8. Dhillon S, Sander JWAS. Epilepsy. In: Walker R, Edwards C, eds. Clinical Pharmacy and Therapeutics, 2 nd ed. Edinburgh: Churchill Livingstone, 1999:445.
  9. Karceski S, Morrell M, Carpenter D. The expert consensus guideline series: treatment of epilepsy. Epilep and Behav 2001;2:1-50. Go to original source...
  10. Diaz - Arrastia R, Agostini M A, van Ness P C. Rozvíjejíci se postupy léčby epilepsie. JAMA - CS 2003;1:31-34.
  11. Iannetti P, Raucci U, Zuccaro P et al. Lamotrigine hypersensitivity in childhood epilepsy. Epilepsia 1998;39:502-507. Go to original source... Go to PubMed...
  12. Catania S, Cross H, de Sousa C et al. Paradoxic reaction to lamotrigine in a child with benign focal epilepsy of childhood with centrotemporal spikes. Epilepsia 1999;40:1657-1660. Go to original source... Go to PubMed...
  13. Sinclair DB, Berg M, Breault R. Valproic acid-induced pancreatitis in childhood epilepsy: Case series and review. J. Child Neurol 2004;19:498-502. Go to original source... Go to PubMed...
  14. Iannetti P, Spacile A, Perla FM et al. Visual field constriction in children with epilepsy on vigabatrin treatment. Pediatrics 2000;106:838-842. Go to original source... Go to PubMed...
  15. Ko TS, You SJ, Ahn HS. Vigabatrin and visual field defect in paediatric epilepsy patients. Epilepsia 2003;44:150.
  16. Baker GA, Jacoby A, Buck D et al. Quality of life of people with epilepsy: A european study. Epilepsia 1997;38:353-362. Go to original source... Go to PubMed...
  17. Uijl SG, Uiterwaal CS, Aldenkamp AP et al. Study to improve the treatment of epilepsy (abstract). Epilepsia 2003;44:82.
  18. Temple ME, Robinson RF, Miller JC et al. Frequency and preventability of adverse drug reactions in paediatric patients. Drug Saf 2004;27(11):819-829. Go to original source... Go to PubMed...
  19. Sweetman SC et al. The complete drug reference - antiepileptics. 33rd ed. Martindale, 2002:338-371.
  20. Desai J, Desai M, Wadia P. Monitoring valproate therapy in an epilepsy clinic: Observations and insights into unsual toxicities. Epilepsia 2003;44:119.
  21. Wong ICK, Lhatoo SD. Adverse reactions to new anticonvulsant drugs. Drug Saf 2000;23:35-56. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.